Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics

Liver International

Volumn 27, Issue 2, 2007, Pages 163-173

  Santamaría, Enrique ^a   Muñoz, Javier ^a   Fernández Irigoyen, Joaquín ^a   Prìeto, Jesús ^a   Corrales, Fernando J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Biomarkers; Hepatocellular carcinoma; Mass spectrometry; Proteomics

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; AUTOANTIBODY; BIOLOGICAL MARKER; CALRETICULIN; CATECHOL METHYLTRANSFERASE; CATHEPSIN D; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 8; DNA TOPOISOMERASE; ENOYL COENZYME A HYDRATASE; FERRITIN; FRUCTOSE BISPHOSPHATASE; HAPTOGLOBIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETOHEXOKINASE; METHIONINE ADENOSYLTRANSFERASE; NUCLEOPHOSMIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PREALBUMIN; PROTEIN S 100; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; STATHMIN; STEROL CARRIER PROTEIN 2; TUMOR ANTIGEN; TUMOR MARKER;

APOPTOSIS; BODY FLUID; CARCINOMA CELL; DISEASE ASSOCIATION; DOWN REGULATION; EARLY DIAGNOSIS; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS C; HUMAN; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LIVER LEVEL; MASS SPECTROMETRY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; RELIABILITY; REVIEW; SAMPLING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; VALIDATION PROCESS; ANIMAL; LIVER TUMOR; METABOLISM; METHODOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247596470     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01447.x     Document Type: Review

References (92)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94 (2): 153-6.
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19 (3): 271-85.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-17.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31 (4): 339-46.
5. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl. 1): S113-9.
6. Li C, Tan YX, Zhou H, et al. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 2005; 5 (4): 1125-39.
7. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21 (16): 2593-604.
8. Kim JW, Ye Q, Forgues M, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004; 39 (2): 518-27.
9. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40 (3): 667-76.
10. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001; 98 (26): 15089-94.
11. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004; 3 (10): 960-9.
12. Cox B, Kislinger T, Emili A. Integrating gene and protein expression data: Pattern analysis and profile mining. Methods 2005; 35 (3): 303-14.
13. Anderson NG, Anderson L. The human protein index. Clin Chem 1982; 28: 739-48.
14. Monteoliva L, Albar JP. Differential proteomics: An overview of gel and non-gel based approaches. Brief Funct Genomic Proteomic 2004; 3 (3): 220-39.
15. Diamond DL, Proll SC, Jacobs JM, et al. Hepatoproteomics: Applying proteomic technologies to the study of liver function and disease. Hepatology 2006; 44 (2): 299-308.
16. Gorg A, Obermaier C, Boguth G, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21 (6): 1037-53.
17. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18 (11): 2071-7.
18. Van Den Bergh G, Arckens L. Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr Opin Biotechnol 2004; 15 (1): 38-43.
19. Tannu NS, Hemby SE. Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat Protocols 2006; 1 (1): 1732-4.
20. Zhu H, Bilgin M, Snyder M. Proteomics. Annu Rev Biochem 2003; 72: 783-812.
21. Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol 2003; 7 (1): 55-63.
22. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 (9306): 572-7.
23. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60 (20): 2299-301.
24. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246 (4926): 64-71.
25. Lee CL, Hsiao HH, Lin CW, et al. Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 2003; 3 (12): 2472-86.
26. Yu LR, Zeng R, Shao XX, Wang N, Xu YH, Xia QC. Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis 2000; 21 (14): 3058-68.
27. Yuan Q, An J, Liu DG, et al. Proteomic analysis of differential protein expression in a human hepatoma revertant cell line by using an improved two-dimensional electrophoresis procedure combined with matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2004; 25 (7-8): 1160-8.
28. Zeindl-Eberhart E, Jungblut P, Rabes HM. Expression of tumor-associated protein variants in chemically induced rat hepatomas and transformed rat liver cell lines determined by two-dimensional electrophoresis. Electrophoresis 1994; 15 (3-4): 372-81.
29. Clifton JG, Li X, Reutter W, Hixson DC, Josic D. Comparative proteomics of rat liver and Morris hepatoma 7777 plasma membranes. J Chromatogr B Analyt Technol Biomed Life Sci 2006.
30. Tan TL, Chen WN. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: Potential in identification of early diagnostic markers for HCC. J Clin Virol 2005; 33 (4): 293-8.
31. Kang SM, Shin MJ, Kim JH, Oh JW. Proteomic profiling of cellular proteins interacting with the hepatitis C virus core protein. Proteomics 2005; 5 (8): 2227-37.
32. Choi YW, Tan YJ, Lim SG, Hong W, Goh PY. Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun 2004; 318 (2): 514-9.
33. Mannova P, Fang R, Wang H, et al. Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics 2006; 5 (12): 2319-2325.
34. Cui JF, Liu YK, Pan BS, et al. Differential proteomic analysis of human hepatocellular carcinoma cell line metastasis-associated proteins. J Cancer Res Clin Oncol 2004; 130 (10): 615-22.
35. Cui JF, Liu YK, Zhang LJ, et al. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis in vitro. Proteomics 2006; 6 (22): 5953-61.
36. Ding SJ, Li Y, Shao XX, et al. Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004; 4 (4): 982-94.
37. Li C, Hong Y, Tan YX, et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 2004; 3 (4): 399-409.
38. Szabo E, Paska C, Kaposi Novak P, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res 2004; 10 (1): 5-11.
39. Waris G, Siddiqui A. Regulatory mechanisms of viral hepatitis B and C. J Biosci 2003; 28 (3): 311-21.
40. Kim W, Oe Lim S, Kim JS, et al. Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 2003; 9 (15): 5493-500.
41. Yokoyama Y, Kuramitsu Y, Takashima M, et al. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 2004; 4 (7): 2111-6.
42. Blanc JF, Lalanne C, Plomion C, et al. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 2005; 5 (14): 3778-89.
43. Takashima M, Kuramitsu Y, Yokoyama Y, et al. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 2005; 5 (6): 1686-92.
44. Lee TH, Tai DI, Cheng CJ, et al. Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B-and C-related hepatocarcinogenesis: Identification by functional proteomics. J Biomed Sci 2006; 13 (1): 27-39.
45. Kim J, Kim SH, Lee SU, et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 2002; 23 (24): 4142-56.
46. Kuramitsu Y, Harada T, Takashima M, et al. Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus. Electrophoresis 2006; 27 (8): 1651-8.
47. Lim SO, Park SJ, Kim W, et al. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002; 291 (4): 1031-7.
48. Lee IN, Chen CH, Sheu JC, et al. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 2005; 4 (6): 2062-9.
49. Luk JM, Lam CT, Siu AF, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 2006; 6 (3): 1049-57.
50. Song HY, Liu YK, Feng JT, et al. Proteomic analysis on metastasis-associated proteins of human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol 2006; 132 (2): 92-8.
51. Nissom PM, Lo SL, Lo JC, et al. Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma. FEBS Lett 2006; 580 (9): 2216-26.
52. Zeindl-Eberhart E, Haraida S, Liebmann S, et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 2004; 39 (2): 540-9.
53. Kawakami T, Hoshida Y, Kanai F, et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005; 5 (16): 4287-95.
54. He QY, Lau GK, Zhou Y, et al. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics 2003; 3 (5): 666-74.
55. Steel LF, Shumpert D, Trotter M, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 2003; 3 (5): 601-9.
56. Martin-Ventura JL, Duran MC, Blanco-Colio LM, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004; 110 (15): 2216-9.
57. Feng JT, Liu YK, Song HY, et al. Heat-shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 2005; 5 (17): 4581-8.
58. Li Y, Tang ZY, Tian B, et al. Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: Study in nude mice model and clinical patients. J Cancer Res Clin Oncol 2006; 132 (8): 515-20.
59. Chignard N, Shang S, Wang H, et al. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology 2006; 130 (7): 2010-22.
60. Comunale MA, Mattu TS, Lowman MA, et al. Comparative proteomic analysis of d - N -glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics 2004; 4 (3): 826-38.
61. Comunale MA, Lowman M, Long RE, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006; 5 (2): 308-15.
62. Ang IL, Poon TC, Lai PB, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: A glycoproteomic approach. J Proteome Res 2006; 5 (10): 2691-700.
63. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005; 41 (1): 40-7.
64. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41 (3): 634-42.
65. Ward DG, Cheng Y, N'Kontchou G, et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer 2006; 95 (10): 1379-83.
66. Lee IN, Chen CH, Sheu JC, et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006; 6 (9): 2865-73.
67. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002; 1 (3): 197-203.
68. Takashima M, Kuramitsu Y, Yokoyama Y, et al. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics 2006; 6 (13): 3894-900.
69. Cui F, Wang Y, Wang J, et al. The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice. Proteomics 2006; 6 (2): 498-504.
70. Cantoni GL. S -Adenosylmethionine; a new intermediate formed enzymatically from l -methionine and adenosinetriphosphate. J Biol Chem 1953; 204 (1): 403-16.
71. Mato JM, Corrales FJ, Lu SC, Avila MA. S -Adenosylmethionine: A control switch that regulates liver function. FASEB J 2002; 16 (1): 15-26.
72. Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000; 33 (6): 907-14.
73. Cabrero C, Duce AM, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight form of S-adenosyl-l-methionine synthetase in human liver cirrhosis. Hepatology 1988; 8 (6): 1530-4.
74. Duce AM, Ortiz P, Cabrero C, Mato JM. S-adenosyl-l-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology 1988; 8 (1): 65-8.
75. Gaull GE, Tallan HH, Lonsdale D, Przyrembel H, Schaffner F, Von Bassewitz DB. Hypermethioninemia associated with methionine adenosyltransferase deficiency: Clinical, morphologic, and biochemical observations on four patients. J Pediatr 1981; 98 (5): 734-41.
76. Gil B, Casado M, Pajares MA, et al. Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. Hepatology 1996; 24 (4): 876-81.
77. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997; 73 (3): 265-80.
78. Mato JM, Camara J, Fernandez De Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30 (6): 1081-9.
79. Lu SC, Alvarez L, Huang ZZ, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci USA 2001; 98 (10): 5560-5.
80. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA, et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 2002; 16 (10): 1292-4.
81. Santamaria E, Avila MA, Latasa MU, et al. Functional proteomics of nonalcoholic steatohepatitis: Mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA 2003; 100 (6): 3065-70.
82. Fernandez-Irigoyen J, Santamaria E, Sesma L, et al. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. Proteomics 2005; 5 (18): 4964-4972.
83. Liang CR, Leow CK, Neo JC, et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2005; 5 (8): 2258-71.
84. Santamaria E, Munoz J, Fernandez-Irigoyen J, et al. Molecular profiling of hepatocellular carcinoma in mice with a chronic deficiency of hepatic S-adenosylmethionine: Relevance in human liver diseases. J Proteome Res 2006; 5 (4): 944-53.
85. Olsen JV, Blagoev B, Gnad F, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 127 (3): 635-48.
86. Zhang H, Aebersold R. Isolation of glycoproteins and identification of their N-linked glycosylation sites. Methods Mol Biol 2006; 328: 177-85.
87. Diamandis EP. Point: Proteomic patterns in biological fluids do they represent the future of cancer diagnostics? Clin Chem 2003; 49 (8): 1272-5.
88. Cornett DS, Mobley JA, Dias EC, et al. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics 2006; 5 (10): 1975-83.
89. Meistermann H, Norris JL, Aerni HR, et al. Biomarker discovery by imaging mass spectrometry: Transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics 2006; 5 (10): 1876-86.
90. Haab BB, Paulovich AG, Anderson NL, et al. A reagent resource to identify proteins and peptides of interest for the cancer community: A workshop report. Mol Cell Proteomics 2006; 5 (10): 1996-2007.
91. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: A higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006; 6 (12): 961-7.
92. Domon B, Aebersold R. Challenges and opportunities in proteomics data analysis. Mol Cell Proteomics 2006; 5 (10): 1921-6.